Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 1/2020

Open Access 01-01-2020 | Glaucoma | Review

Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review

Authors: Marcelo Luís Occhiutto, Raul C. Maranhão, Vital Paulino Costa, Anastasios G. Konstas

Published in: Advances in Therapy | Issue 1/2020

Login to get access

Abstract

Glaucoma is the second leading cause of blindness worldwide. Even though significant advances have been made in its management, currently available antiglaucoma therapies suffer from considerable drawbacks. Typically, the success and efficacy of glaucoma medications are undermined by their limited bioavailability to target tissues and the inadequate adherence demonstrated by patients with glaucoma. The latter is due to a gradual decrease in tolerability of lifelong topical therapies and the significant burden to patients of prescribed stepwise antiglaucoma regimens with frequent dosing which impact quality of life. On the other hand, glaucoma surgery is restricted by the inability of antifibrotic agents to efficiently control the wound healing process without causing severe collateral damage and long-term complications. Evolution of the treatment paradigm for patients with glaucoma will ideally include prevention of retinal ganglion cell degeneration by the successful delivery of neurotrophic factors, anti-inflammatory drugs, and gene therapies. Nanotechnology-based treatments may surpass the limitations of currently available glaucoma therapies through optimized targeted drug delivery, increased bioavailability, and controlled release. This review addresses the recent advances in glaucoma treatment strategies employing nanotechnology, including medical and surgical management, neuroregeneration, and neuroprotection.
Literature
1.
2.
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–51.PubMedPubMedCentral
3.
4.
Stein JD, Lee PP. Screening for glaucoma. In: Yanoff M, Duker JS, editors. Ophthalmology. Amsterdan, The Netherlands: Elsevier Sanders; 2009, p. 1007.
5.
Heiji A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–79.
6.
The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol. 2000;130(4):429–40.
7.
Medeiros FA, Weinreb RN. Medical backgrounders: glaucoma. Drugs Today (Barc). 2002;38(8):563–70.
8.
9.
Abrams KL. Medical and surgical management of the glaucoma patient. Clin Tech Small Anim Pract. 2001;16(1):71–6.PubMed
10.
Levin LA, Crowe ME, Quigley HA. Lasker/IRRF initiative on astrocytes and glaucomatous neurodegeneration participants. Neuroprotection for glaucoma: requirements for clinical translation. Exp Eye Res. 2017;157:34–7.PubMed
11.
Cetinel S, Montemagno C. Nanotechnology applications for glaucoma. Asia Pac J Ophthalmol (Phila). 2016;5(1):70–8.
12.
Goyal G, Garg T, Rath G, et al. Current nanotechnological strategies for treating glaucoma. Crit Rev Ther Drug Carrier Syst. 2014;31(5):365–405.PubMed
13.
Cardigos J, Ferreira Q, Crisóstomo S, et al. Nanotechnology-ocular devices for glaucoma treatment: a literature review. Curr Eye Res. 2019;44(2):111–7.PubMed
14.
Foldvari M. Noninvasive ocular drug delivery: potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma. J Glaucoma. 2014;23(8 Suppl 1):S80–2.PubMed
15.
Kim NJ, Harris A, Gerber A, et al. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br J Ophthalmol. 2014;98(4):427–31.PubMed
16.
Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012;119:979–86.PubMed
17.
18.
Agarwal R, Gupta SK, Agarwal P, et al. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol. 2009;57(4):257–66.PubMedPubMedCentral
19.
Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–20.PubMed
20.
Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–63.PubMedPubMedCentral
21.
Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711–6.PubMedPubMedCentral
22.
Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431–6.PubMed
23.
Loch C, Zakelj S, Kristl A, et al. Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes. Eur J Pharm Sci. 2012;47:131–8.PubMed
24.
Chiang CH, Schoenwald RD. Ocular pharmacokinetic models of clonidine-3H hydrochloride. J Pharmacokinet Biopharm. 1986;14(2):175–211.PubMed
25.
Schoenwald RD. Ocular pharmacokinetics/pharmacodynamics. In: Mitra AK, editor. Ophthalmic drug delivery systems. 2nd ed. New York: Dekker, Inc.; 2003.
26.
Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979;23(5):279–96.PubMed
27.
Del Amo EM, Rimpela AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–85.PubMed
28.
Shikamura Y, Yamazaki Y, Matsunaga T, et al. Hydrogel ring for topical drug delivery to the ocular posterior segment. Curr Eye Res. 2016;41:653–61.PubMed
29.
Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6:735–54.PubMedPubMedCentral
30.
Pelkonen L, Tengvall-Unadike U, Ruponen M, et al. Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts. Eur J Pharm Sci. 2017;109:162–8.PubMed
31.
Carreon TA, Edwards G, Wang H, et al. Segmental outflow of aqueous humor in mouse and human. Exp Eye Res. 2017;158:59–66.PubMed
32.
Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: a review. Exp Eye Res. 2017;158:94–111.PubMed
33.
Yücel YH. Discovery of lymphatics in the human eye and implications. Can J Ophthalmol. 2010;45(2):115–7.PubMed
34.
Tomczyk-Socha M, Turno-Kręcicka A. A novel uveolymphatic drainage pathway-possible new target for glaucoma treatment. Lymphat Res Biol. 2017;15(4):360–3.PubMed
35.
Yücel Y, Gupta N. Lymphatic drainage from the eye: a new target for therapy. Prog Brain Res. 2015;220:185–98.PubMed
36.
Lee SJ, Kim SJ, Kim ES, et al. Trans-scleral permeability of Oregon Green 488. J Ocul Pharmacol Ther. 2008;24:579–86.PubMedPubMedCentral
37.
Del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res. 2015;137:111–24.PubMed
38.
Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26:584–7.PubMed
39.
Hamalainen KM, Kananen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci. 1997;38:627–34.PubMed
40.
Sponsel WE, Terry S, Khuu HD, Lam KW, Frenzel H. Periocular accumulation of timolol and betaxolol in patients with glaucoma under long-term therapy. Surv Ophthalmol. 1999;43(suppl 1):S210–3.PubMed
41.
Holló G, Whitson JT, Faulkner R, et al. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Invest Ophthalmol Vis Sci. 2006;47(1):235–40.PubMed
42.
Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye (Lond). 2011;25:578–86.
43.
Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. 2010;(2):CD006539.
44.
Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151:671–81.PubMed
45.
Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol. 2012;23:144–54.PubMed
46.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMed
47.
Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: cellular basis and development. Vision Res. 2017;139:123–37.PubMedPubMedCentral
48.
Liu G, Molas M, Grossmann GA, et al. Biological properties of poly-l-lysine-DNA complexes generated by cooperative binding of the polycation. J Biol Chem. 2001;276(37):34379–87.PubMed
49.
Nagarwal RC, Kant S, Singh PN, et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136(1):2–13.PubMed
50.
Singh Y, Meher JG, Raval K, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;28(252):28–49.
51.
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60.PubMed
52.
Akbarzadeh A, Khalilov R, Mostafavi E, et al. Role of dendrimers in advanced drug delivery and biomedical applications: a review. Exp Oncol. 2018;40(3):178–83.PubMed
53.
Cheng B, He H, Huang T, et al. Gold nanosphere gated mesoporous silica nanoparticle responsive to near-infrared light and redox potential as a theranostic platform for cancer therapy. J Biomed Nanotechnol. 2016;12(3):435–49.PubMedPubMedCentral
54.
Gao W, Zhang Y, Zhang Q, et al. Nanoparticle–hydrogel: a hybrid biomaterial system for localized drug delivery. Ann Biomed Eng. 2016;44(6):2049–61.PubMedPubMedCentral
55.
Lu Y, Qi J, Dong X, et al. The in vivo fate of nanocrystals. Drug Discov Today. 2017;22(4):744–50.PubMed
56.
Zhang Y, Ren K, He Z, et al. Development of inclusion complex of brinzolamide with hydroxypropyl-β-cyclodextrin. Carbohydr Polym. 2013;98(1):638–43.PubMed
57.
Chaudhary HM, Duttagupta AS, Jadhav KR, et al. Nanodiamonds as a new horizon for pharmaceutical and biomedical applications. Curr Drug Deliv. 2015;12(3):271–81.PubMed
58.
Prajapati VD, Jani GK, Kapadia JR. Current knowledge on biodegradable microspheres in drug delivery. Expert Opin Drug Deliv. 2015;12(8):1283–99.PubMed
59.
Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;10(185):22–36.
60.
Haidar MK, Eroglu H. Nanofibers: new insights for drug delivery and tissue engineering. Curr Top Med Chem. 2017;17(13):1564–79.PubMed
61.
Talevi A, Gantner ME, Ruiz ME. Applications of nanosystems to anticancer drug therapy (Part I. Nanogels, nanospheres, nanocapsules). Recent Pat Anticancer Drug Discov. 2014;9(1):83–98.PubMed
62.
Priwitaningrum DL, Blonde JG, Sridhar A, et al. Tumor stroma-containing 3D spheroid arrays: a tool to study nanoparticle penetration. J Control Release. 2016;244(Pt B):257–68.PubMed
63.
Hornung A, Poettler M, Friedrich RP, et al. Treatment efficiency of free and nanoparticle-loaded mitoxantrone for magnetic drug targeting in multicellular tumor spheroids. Molecules. 2015;20(10):18016–30.PubMedPubMedCentral
64.
Yang L, Yin T, Liu Y, et al. Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for Alzheimer’s disease treatment. Acta Biomater. 2016;46:177–90.PubMed
65.
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl. 1):S131–55.PubMed
66.
Tamboli V, Mishra GP, Mitrat AK. Polymeric vectors for ocular gene delivery. Ther Deliv. 2011;2:523–36.PubMed
67.
Wang J, Huang Y, David AE, et al. Magnetic nanoparticles for MRI of brain tumors. Curr Pharm Biotechnol. 2012;13(12):2403–16.PubMed
68.
Chen J, Patil S, Seal S, et al. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol. 2006;1:142–50.PubMed
69.
Salem HF, Ahmed SM, Omar MM. Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery. Drug Des Devel Ther. 2016;13(10):277–95.
70.
Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;19:215–33.
71.
Venishetty VK, Komuravelli R, Kuncha M, et al. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine. 2013;9(1):111–21.PubMed
72.
Liu D, Lian Y, Fang Q, et al. Hyaluronic-acid-modified lipid-polymer hybrid nanoparticles as an efficient ocular delivery platform for moxifloxacin hydrochloride. Int J Biol Macromol. 2018;17(116):1026–36.
73.
Jonas JB, Aung T, Boune RR, et al. Glaucoma. Lancet. 2017;390:2083–93.
74.
Chrai SS, Robinson JR. Corneal permeation of topical pilocarpine nitrate in the rabbit. Am J Ophthalmol. 1974;77(5):735–9.PubMed
75.
Lazare R, Horlington M. Pilocarpine levels in the eyes of rabbits following topical application. Exp Eye Res. 1975;21(3):281–7.PubMed
76.
Plazoneet J, Grove M, Durr C, et al. Recent advances in pilocarpine delivery. In: Saettone MF, Bucci M, Speiser P, editors. Ophthalmic drug delivery: biopharmaceutical, technological and clinical aspects. Padova: Springer & Liviana; 1987. p. 122.
77.
Pepic I, Jalsenjak N, Jalsenjak I. Micellar solutions of triblock copolymer surfactants with pilocarpine. Int J Pharm. 2004;272:57–64.PubMed
78.
Jarho P, Järvinen K, Urtti A, et al. Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J Pharm Pharmacol. 1996;48(3):263–9.PubMed
79.
Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102(1):23–38.PubMed
80.
Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int J Pharm. 2000;198:29–38.PubMed
81.
Aktaş Y, Unlü N, Orhan M, et al. Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine. Drug Dev Ind Pharm. 2003;29(2):223–30.PubMed
82.
Lee CH, Li YJ, Huang CC, et al. Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment. Nanoscale. 2017;9(32):11754–64.PubMed
83.
Casolaro M, Casolaro I, Lamponi S. Stimuli-responsive hydrogels for controlled pilocarpine ocular delivery. Eur J Pharm Biopharm. 2012;80(3):553–61.PubMed
84.
Li J, Wu L, Wu W, et al. A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int J Pharm. 2013;455(1–2):75–84.PubMed
85.
Orasugh JT, Sarkar G, Saha NR, et al. Effect of cellulose nanocrystals on the performance of drug loaded in situ gelling thermo-responsive ophthalmic formulations. Int J Biol Macromol. 2019;1(124):235–45.
86.
Kao HJ, Lin HR, Lo YL, et al. Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol. 2006;58(2):179–86.PubMed
87.
Heel RC, Brogden RN, Speight TM, Avery GF. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs. 1979;17(1):38–55.PubMed
88.
Fukuda M, Sasaki H. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes. J Ocul Pharmacol Ther. 2015;31(1):57–60.PubMed
89.
Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87(5):447–50.PubMed
90.
Maulvi FA, Patil RJ, Desai AR, et al. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: in vitro and in vivo evaluation. Acta Biomater. 2019;1(86):350–62.
91.
Shokry M, Hathout RM, Mansour S. Exploring gelatin nanoparticles as novel nanocarriers for timolol maleate: augmented in vivo efficacy and safe histological profile. Int J Pharm. 2018;545(1–2):229–39.PubMed
92.
Jung HJ, Chauhan A. Extended release of timolol from nanoparticle-loaded fornix insert for glaucoma therapy. J Ocular Pharmacol Ther. 2013;29(2):229–35.
93.
Shafaa MW, Sabra NM, Fouad RA. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits. Biopharm Drug Dispos. 2011;32(9):507–17.PubMed
94.
Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005;290(1):155–9.PubMed
95.
Gagandeep, Garg T, Malik B, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014;53:10–6.PubMed
96.
Fulgêncio Gde O, Viana FA, Ribeiro RR, et al. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J Ocul Pharmacol Ther. 2012;28(4):350–8.PubMed
97.
Siafaka PI, Titopoulou A, Koukaras EN, et al. Chitosan derivatives as effective nanocarriers for ocular release of timolol drug. Int J Pharm. 2015;495(1):249–64.PubMed
98.
Bertram JP, Saluja SS, McKain J, et al. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months. J Microencapsul. 2009;26:18–26.PubMed
99.
Ilka R, Mohseni M, Kianirad M, et al. Nanogel-based natural polymers as smart carriers for the controlled delivery of timolol maleate through the cornea for glaucoma. Int J Biol Macromol. 2018;1(109):955–62.
100.
Tan G, Yu S, Pan H, et al. Bioadhesive chitosan-loaded liposomes: a more efficient and higher permeable ocular delivery platform for timolol maleate. Int J Biol Macromol. 2017;94(Pt A):355–63.PubMed
101.
Zhang HH, Luo QH, Yang ZJ, et al. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Deliv. 2011;18(7):502–10.PubMed
102.
Zhao R, Li J, Wang J, et al. Development of timolol-loaded galactosylated chitosan nanoparticles and evaluation of their potential for ocular drug delivery. AAPS PharmSciTech. 2017;18(4):997–1008.PubMed
103.
Yu S, Wang QM, Wang X, et al. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm. 2015;480(1–2):128–36.PubMed
104.
Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther. 1997;74(1):1–20.PubMed
105.
Holló G. Carbonic anhydrase inhibitors. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma. 2nd ed. Philadelphia: Elsevier Saunders; 2015. p. 559.
106.
Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19(1):87–112.PubMed
107.
Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(10108):2183–93.PubMed
108.
Carta F, Scozzafava A, Supuran CT. Sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat. 2012;22(7):747–58.PubMed
109.
Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat. 2000;10:575–600.
110.
Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev. 1967;47(4):595–781.PubMed
111.
Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–59.PubMed
112.
Ilies M, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg Med Chem. 2000;8(8):2145–55.PubMed
113.
Winum JY, Casini A, Mincione F, et al. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-d-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004;14(1):225–9.PubMed
114.
DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119–29.PubMed
115.
Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000;199(2):119–27.PubMed
116.
Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol. 1977;95(8):1378–82.PubMed
117.
Kaur IP, Kapil M, Smitha R, et al. Development of topically effective formulations of acetazolamide using HP-beta-CD-polymer co-complexes. Curr Drug Deliv. 2004;1(1):65–72.PubMed
118.
Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst. 1999;16(1):85–146.PubMed
119.
Kaur IP, Smitha R, Aggarwal D, et al. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm. 2002;248(1–2):1–14.PubMed
120.
Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985;103(7):963–6.PubMed
121.
Loftsson T, Frithriksdóttir H, Stefánsson E, et al. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol. 1994;46(6):503–4.PubMed
122.
El-Gazaierly O, Hikal AH. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm. 1997;158(2):121–7.
123.
Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm. 2007;338(1–2):21–6.PubMed
124.
Duarte AR, Roy C, Vega-González A, Duarte CM, Subra-Paternault P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int J Pharm. 2007;332(1–2):132–9.PubMed
125.
Rathod LV, Kapadia R, Sawant KK. A novel nanoparticle impregnated ocular insert for enhanced bioavailability to posterior segment of eye: in vitro, in vivo and stability studies. Mater Sci Eng C Mater Biol Appl. 2017;1(71):529–40.
126.
Singh J, Chhabra G, Pathak K. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. Ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm. 2014;40(9):1223–32.PubMed
127.
Bravo-Osuna I, Vicario-de-la-Torre M, Andrés-Guerrero V, et al. Novel water-soluble mucoadhesive carbosilane dendrimers for ocular administration. Mol Pharm. 2016;13(9):2966–76.PubMed
128.
Mishra V, Jain NK. Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits. Int J Pharm. 2014;461(1–2):380–90.PubMed
129.
Morsi N, Ibrahim M, Refai H, et al. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur J Pharm Sci. 2017;15(104):302–14.
130.
Verma P, Gupta RN, Jha AK, et al. Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide. Drug Deliv. 2013;20(7):269–76.PubMed
131.
Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol. 1997;42(2):137–51.PubMed
132.
Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113(8):1009–16.PubMed
133.
Martens-Lobenhoffer J, Banditt P. Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41(3):197–205.PubMed
134.
Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–8.PubMed
135.
Shinde U, Ahmed MH, Singh K. Development of dorzolamide loaded 6-O-carboxymethyl chitosan nanoparticles for open angle glaucoma. J Drug Deliv. 2013;2013:562727.PubMedPubMedCentral
136.
Jansook P, Stefánsson E, Thorsteinsdóttir M, et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm. 2010;76(2):208–14.PubMed
137.
Fu J, Sun F, Liu W, et al. Subconjunctival delivery of dorzolamide-loaded poly(ether-anhydride) microparticles produces sustained lowering of intraocular pressure in rabbits. Mol Pharm. 2016;13(9):2987–95.PubMedPubMedCentral
138.
Katiyar S, Pandit J, Mondal RS, et al. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym. 2014;15(102):117–24.
139.
Kouchak M, Malekahmadi M, Bavarsad N, et al. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Drug Dev Ind Pharm. 2018;44(8):1239–42.PubMed
140.
Gudmundsdottir BS, Petursdottir D, Asgrimsdottir GM, et al. γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man. J Ocul Pharmacol Ther. 2014;30(1):35–41.PubMed
141.
Iester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008;2(3):517–23.PubMedPubMedCentral
142.
Kadam RS, Jadhav G, Ogidigben M, et al. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos. 2011;39(9):1529–37.PubMedPubMedCentral
143.
Silver LH, the Brinzolamide Comfort Study Group. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution. Results from two multicenter comfort studies. Surv Ophthalmol. 2000;44:141–5.
144.
Tsukamoto H, Noma H, Mukai S, et al. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther. 2005;21(5):395–9.PubMed
145.
Wu W, Li J, Wu L, et al. Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation. AAPS Pharm Sci Tech. 2013;14(3):1063–71.
146.
Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014;467(1–2):34–41.PubMed
147.
Ikuta Y, Aoyagi S, Tanaka Y, et al. Creation of nano eye-drops and effective drug delivery to the interior of the eye. Sci Rep. 2017;14(7):44229.
148.
Mahboobian MM, Seyfoddin A, Rupenthal ID, et al. Formulation development and evaluation of the therapeutic efficacy of brinzolamide containing nanoemulsions. Iran J Pharm Res. 2017;16(3):847–57.PubMedPubMedCentral
149.
Wang F, Bao X, Fang A, et al. Nanoliposome-encapsulated brinzolamide-hydropropyl-β-cyclodextrin inclusion complex: a potential therapeutic ocular drug-delivery system. Front Pharmacol. 2018;13(9):91.
150.
Salama HA, Ghorab M, Mahmoud AA, et al. PLGA nanoparticles as subconjunctival injection for management of glaucoma. AAPS PharmSciTech. 2017;18(7):2517–28.PubMed
151.
Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1):8–14.PubMed
152.
Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3(2):275–87.PubMed
153.
Konstas AG, Stewart WC, Topouzis F, et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol. 2001;131(6):729–33.PubMed
154.
Prabhu P, Nitish KR, Koland M, et al. Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system. J Young Pharm. 2010;2(4):356–61.PubMedPubMedCentral
155.
Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-Eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1087–101.PubMedPubMedCentral
156.
Chiang B, Kim YC, Doty AC, et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J Control Release. 2016;28(228):48–57.
157.
Ibrahim MM, Abd-Elgawad AH, Soliman OA, et al. Natural bioadhesive biodegradable nanoparticle-based topical ophthalmic formulations for management of glaucoma. Transl Vis Sci Technol. 2015;4(3):12.PubMedPubMedCentral
158.
El-Salamouni NS, Farid RM, El-Kamel AH, et al. Nanostructured lipid carriers for intraocular brimonidine localisation: development, in vitro and in vivo evaluation. J Microencapsul. 2018;35(1):102–13.PubMed
159.
Pek YS, Wu H, Mohamed ST, et al. Long-term subconjunctival delivery of brimonidine tartrate for glaucoma treatment using a microspheres/carrier system. Adv Healthc Mater. 2016;5(21):2823–31.PubMed
160.
Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53(Suppl 1):S69–84.PubMed
161.
Tanna AP, Lin AB. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr Opin Ophthalmol. 2015;26(2):116–20.PubMed
162.
Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45–52.PubMed
163.
Wong TT, Novack GD, Natarajan JV, et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res. 2014;4(4):303–9.PubMed
164.
Giarmoukakis A, Labiris G, Sideroudi H, et al. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results. Exp Eye Res. 2013;112:29–36.PubMed
165.
Natarajan JV, Ang M, Darwitan A, et al. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomed. 2012;7:123–31.
166.
Cheng YH, Tsai TH, Jhan YY, et al. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohydr Polym. 2016;25(144):390–9.
167.
Fahmy HM, Saad EAES, Sabra NM, et al. Treatment merits of latanoprost/thymoquinone—encapsulated liposome for glaucomatus rabbits. Int J Pharm. 2018;548(1):597–608.PubMed
168.
Rodriguez-Aller M, Guinchard S, Guillarme D, et al. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance. Eur J Pharm Biopharm. 2015;95(Pt B):203–14.PubMed
169.
Franca JR, Foureaux G, Fuscaldi LL, et al. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation. PLoS One. 2014;9(4):e95461.PubMedPubMedCentral
170.
Di Trani N, Jain P, Chua CYX, et al. Nanofluidic microsystem for sustained intraocular delivery of therapeutics. Nanomedicine. 2019;16:1–9.PubMed
171.
Lambert WS, Carlson BJ, van der Ende AE, et al. Nanosponge-mediated drug delivery lowers intraocular pressure. Transl Vis Sci Technol. 2015;4(1):1.PubMedPubMedCentral
172.
Aref AA, Gedde SJ, Budenz DL. Glaucoma drainage implant surgery. Dev Ophthalmol. 2017;59:43–52.PubMed
173.
Ayyala RS, Duarte JL, Sahiner N. Glaucoma drainage devices: state of the art. Expert Rev Med Devices. 2006;3(4):509–21.PubMed
174.
Chaudhry M, Grover S, Baisakhiya S, et al. Artificial drainage devices for glaucoma surgery: an overview. Nepal J Ophthalmol. 2012;4(2):295–302.PubMed
175.
176.
Hong CH, Arosemena A, Zurakowski D, et al. Glaucoma drainage devices: a systematic literature review and current controversies. Surv Ophthalmol. 2005;50(1):48–60.PubMed
177.
Ponnusamy T, Yu H, John VT, et al. A novel antiproliferative drug coating for glaucoma drainage devices. J Glaucoma. 2014;23(8):526–34.PubMed
178.
Pan T, Brown JD, Ziaie B. An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc. 2006;1:3174–7.
179.
Harake RS, Ding Y, Brown JD, et al. Design, fabrication, and in vitro testing of an anti-biofouling glaucoma micro-shunt. Ann Biomed Eng. 2015;43(10):2394–405.PubMed
180.
Popat KC, Desai TA. Poly(ethylene glycol) interfaces: an approach for enhanced performance of microfluidic systems. Biosens Bioelectron. 2004;19(9):1037–44.PubMed
181.
Shokrollahi H. Structure, synthetic methods, magnetic properties and biomedical applications of ferrofluids. Mater Sci Eng C Mater Biol Appl. 2013;33(5):2476–87.PubMed
182.
183.
Paschalis EI, Chodosh J, Sperling RA, et al. A novel implantable glaucoma valve using ferrofluid. PLoS One. 2013;8(6):e67404.PubMedPubMedCentral
184.
Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314–46.PubMed
185.
Costa VP, Spaeth GL, Eiferman RA, Orengo-Nania S. Wound healing modulation in glaucoma filtration surgery. Ophthalmic Surg. 1993;24:152–70.PubMed
186.
Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;19(4):CD002897.
187.
The Fluorouracil Filtering Surgery Study Group. Three-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1993;115:82–92.
188.
Hou Z, Wei H, Wang Q, et al. New method to prepare mitomycin C loaded PLA-nanoparticles with high drug entrapment efficiency. Nanoscale Res Lett. 2009;4(7):732–7.PubMedPubMedCentral
189.
Gomes dos Santos AL, Bochot A, Doyle A, et al. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release. 2006;112(3):369–81.PubMed
190.
Desai MA, Gedde SJ, Feuer WJ, et al. Practice preferences for glaucoma surgery: a survey of the American Glaucoma Society in 2008. Ophthal Surg Lasers Imaging. 2011;42:202–8.
191.
Occhiutto ML, Freitas FR, Lima PP, Maranhão RC, Costa VP. Paclitaxel associated with lipid nanoparticles as a new antiscarring agent in experimental glaucoma surgery. Invest Ophthalmol Vis Sci. 2016;57(3):971–8.PubMed
192.
Duan Y, Guan X, Ge J, et al. Cationic nano-copolymers mediated IKKbeta targeting siRNA inhibit the proliferation of human Tenon’s capsule fibroblasts in vitro. Mol Vis. 2008;14:2616–28.PubMedPubMedCentral
193.
Ye H, Qian Y, Lin M, et al. Cationic nano-copolymers mediated IKKβ targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery. Mol Vis. 2010;26(16):2502–10.
194.
Paula JS, Ribeiro VR, Chahud F, et al. Bevacizumab-loaded polyurethane subconjunctival implants: effects on experimental glaucoma filtration surgery. J Ocul Pharmacol Ther. 2013;29(6):566–73.PubMedPubMedCentral
195.
Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50(11):5217–25.PubMed
196.
Grewal DS, Jain R, Kumar H, Grewal SPS. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology. 2008;115(12):2141–5.PubMed
197.
Vandewalle E, Abegão Pinto L, Van Bergen T, et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014;98(1):73–8.PubMed
198.
Han Q, Wang Y, Li X, et al. Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery. J Mater Sci Mater Med. 2015;26(8):225.PubMed
199.
Gupta N, Yücel YH. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol. 2007;18(2):110–4.PubMed
200.
Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson memorial lecture. Am J Ophthalmol. 1996;121:473–83.PubMed
201.
Allen SJ, Watson JJ, Shoemark DK, et al. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155–75.PubMed
202.
Frasson M, Picaud S, Léveillard T, et al. Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. Invest Ophthalmol Vis Sci. 1999;40(11):2724–34.PubMed
203.
Checa-Casalengua P, Jiang C, Bravo-Osuna I, et al. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release. 2011;156(1):92–100.PubMed
204.
Ward MS, Khoobehi A, Lavik EB, et al. Neuroprotection of retinal ganglion cells in DBA/2 J mice with GDNF-loaded biodegradable microspheres. J Pharm Sci. 2007;96(3):558–68.PubMed
205.
Jiang C, Moore MJ, Zhang X, et al. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007;24(13):1783–92.
206.
García-Caballero C, Prieto-Calvo E, Checa-Casalengua P, et al. Six month delivery of GDNF from PLGA/vitamin E biodegradable microspheres after intravitreal injection in rabbits. Eur J Pharm Sci. 2017;30(103):19–26.
207.
Clatterbuck RE. Cliliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. Proc Natl Acad Sci USA. 1993;90:2222–6.PubMedPubMedCentral
208.
Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature. 1997;386(6623):395–9.PubMed
209.
Hagg T, Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci USA. 1993;90(13):6315–9.PubMedPubMedCentral
210.
Sendtner M, Schmalbruch H, Stockli KA, et al. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature. 1992;358(6386):502–4.PubMed
211.
Nkansah MK, Tzeng SY, Holdt AM, et al. Poly(lactic-co-glycolic acid) nanospheres and microspheres for short- and long-term delivery of bioactive ciliary neurotrophic factor. Biotechnol Bioeng. 2008;100(5):1010–9.PubMed
212.
Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009;50(5):2194–200.PubMed
213.
Kitagawa K, Matsumoto M, Tagaya M, et al. Hyperthermia-induced neuronal protection against ischemic injury in gerbils. J Cereb Blood Flow Metab. 1991;11(3):449e52.
214.
Caprioli J, Kitano S, Morgan JE. Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest Ophthalmol Vis Sci. 1996;37(12):2376e81.
215.
Barbe MF, Tytell M, Gower DJ, et al. Hyperthermia protects against light damage in the rat retina. Science. 1988;241(4874):1817e20.
216.
Yin Y, Henzl MT, Lorber B, et al. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci. 2006;9:843–52.PubMed
217.
Jeun M, Jeoung JW, Moon S, et al. Engineered superparamagnetic Mn0.5Zn0.5Fe2O4 nanoparticles as a heat shock protein induction agent for ocular neuroprotection in glaucoma. Biomaterials. 2011;32(2):387–94.PubMed
218.
Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science. 2017;356(6342):1026–30.PubMed
219.
Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer’s disease: experimental approaches and clinical interventions. J Neurosci Res. 1998;54:1–6.PubMed
220.
Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999;22:219–40.PubMed
221.
Julien JP. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell. 2001;104:581–91.PubMed
222.
Mac Nair CE, Nickells RW. Neuroinflammation in glaucoma and optic nerve damage. Prog Mol Biol Transl Sci. 2015;134:343–63.PubMed
223.
Kawano T, Anrather J, Zhou P, et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med. 2006;12:225–9.PubMed
224.
Kolko M, DeCoster MA, de Turco EB, et al. Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J Biol Chem. 1996;271:32722–8.PubMed
225.
Li G, Luna C, Liton PB, et al. Sustained stress response after oxidative stress in trabecular meshwork cells. Mol Vis. 2007;13:2282–8.PubMedPubMedCentral
226.
Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20:8693–700.PubMedPubMedCentral
227.
Ergorul C, Ray A, Huang W, et al. Hypoxia inducible factor1alpha (HIF-1alpha) and some HIF-1 target genes are elevated in experimental glaucoma. J Mol Neurosci. 2010;42:183–91.PubMedPubMedCentral
228.
Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1–7.PubMed
229.
Dong S, Zeng Q, Mitchell ES, et al. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One. 2012;7(2):e31211.PubMedPubMedCentral
230.
Kim DS, Kim JY, Han Y. Curcuminoids in neurodegenerative diseases. Recent Pat CNS Drug Discov. 2012;7(3):184–204.
231.
Belviranlı M, Okudan N, Atalık KE, et al. Curcumin improves spatial memory and decreases oxidative damage in aged female rats. Biogerontology. 2013;14(2):187–96.PubMed
232.
Wang L, Li C, Guo H, et al. Curcumin inhibits neuronal and vascular degeneration in retina after ischemia and reperfusion injury. PLoS One. 2011;6(8):e23194.PubMedPubMedCentral
233.
Yue YK, Mo B, Zhao J, et al. Neuroprotective effect of curcumin against oxidative damage in BV-2 microglia and high intraocular pressure animal model. J Ocul Pharmacol Ther. 2014;30(8):657–64.PubMed
234.
Kaminaga Y, Nagatsu A, Akiyama T, et al. Production of unnatural glucosides of curcumin with drastically enhanced water solubility by cell suspension cultures of Catharanthus roseus. FEBS Lett. 2003;555(2):311–6.PubMed
235.
Gupta S, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.PubMed
236.
Davis BM, Pahlitzsch M, Guo L, et al. Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Rep. 2018;8(1):11066.PubMedPubMedCentral
237.
238.
Ju WK, Neufeld AH. Cellular localization of cyclooxygenase-1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J Comp Neurol. 2002;452:392–9.PubMed
239.
Wang AG, Lee CM, Wang YC, et al. Up-regulation of cytochrome oxidase in the retina following optic nerve injury. Exp Eye Res. 2002;74:651–9.PubMed
240.
Ju WK, Kim KY, Neufeld AH. Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia. Exp Eye Res. 2003;77:137–45.PubMed
241.
Nadal-Nicolás FM, Rodriguez-Villagra E, Bravo-Osuna I, et al. Ketorolac administration attenuates retinal ganglion cell death after axonal injury. Invest Ophthalmol Vis Sci. 2016;57(3):1183–92.PubMed
242.
Barcia E, Herrero-Vanrell R, Díez A, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res. 2009;89(2):238–45.PubMed
243.
Prow TW. Toxicity of nanomaterials to the eye. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(4):317–33.PubMed
244.
Voigt N, Henrich-Noack P, Kockentiedt S, et al. Toxicity of polymeric nanoparticles in vivo and in vitro. J Nanopart Res. 2014;16(6):2379.
245.
De Matteis V, Rinaldi R. Toxicity assessment in the nanoparticle era. Adv Exp Med Biol. 2018;1048:1–19.PubMed
246.
El-Ansary A, Al-Daihan S, Bacha AB, et al. Toxicity of novel nanosized formulations used in medicine. Methods Mol Biol. 2013;1028:47–74.PubMed
247.
De Jong WH, Van Der Ven LT, Sleijffers A, et al. Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials. 2013;34(33):8333–43.PubMed
Metadata
Title
Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review
Authors
Marcelo Luís Occhiutto
Raul C. Maranhão
Vital Paulino Costa
Anastasios G. Konstas
Publication date
01-01-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01163-6

Other articles of this Issue 1/2020

Advances in Therapy 1/2020 Go to the issue

Review

Pathophysiology and Therapeutic Perspectives of Oxidative Stress and Neurodegenerative Diseases: A Narrative Review

Original Research

Prospective, Multicenter, Cross-Sectional Survey on Dry Eye Disease in Japan

Original Research

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

Original Research

Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer

Original Research

Cost-Effectiveness of Treating Early to Moderate Stage Knee Osteoarthritis with Intra-articular Hyaluronic Acid Compared to Conservative Interventions

Original Research

Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits